Peptide Advertising Rules: What the FTC and FDA Allow in 2026

Quick answer: peptide advertising rules come from three places. The FTC Act bans deceptive ads and false ads for drugs and health products, FDA rules govern prescription drug promotion and bar false or misleading claims for compounded drugs, and state medical boards discipline clinicians whose ads mislead.^[1][2][5] Since September 2025, FDA has sent what it calls “thousands of letters” to drug and telehealth firms, including at least 30 warning letters over compounded GLP-1 marketing.^[12]

Below we explain which law applies to which kind of peptide, and what enforcement in 2025 and 2026 targeted. For related topics, see FDA warning letters on peptides, telehealth peptide prescriptions, and the FDA & Regulation hub.

Which law applies to which peptide

Product	Main ad regulator	Key rules
FDA-approved prescription peptides (e.g., semaglutide, tirzepatide)	FDA	FD&C Act 502(n); 21 CFR 202.1
Compounded peptides	FDA, plus FTC for the telehealth service	FD&C Act 502(a), 502(bb)
Peptides sold as supplements, skin care or services	FTC	FTC Act sections 5 and 12
“Research use only” peptides	FDA treats human-use marketing as evidence of an unapproved drug	FD&C Act 505(a), 301(d)
Any ad by a licensed clinician	State medical board	Board rules on deceptive advertising

The categories overlap. A telehealth GLP-1 program can draw FDA scrutiny for the drug claims and FTC scrutiny for prices, reviews and subscription terms in the same ad.

The FTC Act: sections 5 and 12

Section 5 declares “unfair or deceptive acts or practices in or affecting commerce” unlawful.^[1] Section 12 specifically makes it unlawful to spread a false advertisement to induce the purchase of food, drugs, devices, services or cosmetics.^[2]

How the FTC applies these to health claims is laid out in its Health Products Compliance Guidance, published in December 2022 to replace its 1998 supplement advertising guide.^[3] The core points:

• Health claims need “competent and reliable scientific evidence.”
• For health benefits, that generally means randomized, controlled human trials. Animal studies, test-tube studies and anecdotes are usually not enough on their own.
• The ad as a whole counts, including images, implied claims and influencer posts, not just the literal words.

This matters for peptides like BPC-157 or GHK-Cu, where much of the evidence is from animals or cell studies. An ad promising faster injury healing in people would be hard to substantiate under this standard.

FDA rules for prescription drug ads

For approved prescription drugs, FDA regulates advertising under section 502(n) of the FD&C Act and 21 CFR 202.1.^[5][4] In short, a prescription drug ad must:

• not be false or misleading,
• present a fair balance of benefits and risks, and
• include a summary of side effects, contraindications and effectiveness, or, for TV and radio, a “major statement” of the main risks plus a way to find the full labeling.

On September 9, 2025, FDA announced it would begin rulemaking to end the “adequate provision” approach for broadcast ads that dates to 1997, and to extend oversight to social media promotion.^[10]

Compounded peptides: “same as” claims

Compounded drugs are not FDA-approved, and section 502(bb) makes a compounded drug misbranded if its advertising or promotion is false or misleading.^[5] FDA’s guidance for telehealth companies lists practices it says violate federal law:^[11]

• calling a compounded drug a generic of, or the same as, an approved drug;
• claiming it is FDA-approved or has been evaluated for safety and effectiveness;
• calling it “clinically proven” to work like the approved drug;
• branding that implies the telehealth company made it;
• saying it comes from an “FDA-approved” or “FDA-licensed” pharmacy, since FDA does not approve or license compounding facilities.

Telehealth GLP-1 ad enforcement, 2025–2026

Date	Action
July 2025	FTC complaint against telehealth firm NextMed alleging hidden costs, unsupported average weight-loss claims, fake testimonials and review suppression[8]
September 2025	FDA launches a crackdown on misleading drug ads, including telehealth GLP-1 firms[10]
December 2025	FTC approves final NextMed order: $150,000 payment and bans on misrepresenting costs, results and reviews[9]
February 6, 2026	FDA says it intends to act against non-approved GLP-1 drugs mass-marketed as alternatives to approved ones[14]
March 3, 2026	FDA announces 30 warning letters to telehealth companies over “sameness” claims and misleading branding[12]
June 2026	Further letters, including one citing a claim that a compounding facility was “FDA-licensed”[13]

For how these fit with FDA’s ingredient restrictions, see the FDA peptide compounding crackdown and compounded semaglutide vs Ozempic.

Influencers, testimonials and reviews

Much peptide marketing happens on social media. Three FTC rules apply:

• Endorsement Guides (16 CFR Part 255). Updated in 2023, they require clear disclosure of any material connection between an endorser and a brand, such as payment, free products or affiliate links. Advertisers are liable for misleading endorsements, and an endorsement cannot make a claim the advertiser could not make directly.^[6]
• Consumer Reviews and Testimonials rule (16 CFR Part 465). It bans fake reviews, buying reviews, and certain review suppression.^[7]
• Typical results. The NextMed order requires competent and reliable evidence for claims about average or typical weight loss.^[9]

“Research use only” marketing

Sellers of unapproved peptides often avoid health claims on the product page but make them elsewhere: in blog posts, dosing “guides,” social media videos, or through affiliates. Advertising rules do not stop at the label. When FDA decides whether a product is a drug, it looks at the whole marketing picture, and its warning letters have quoted sellers’ social media posts and product descriptions about weight loss and diabetes as evidence of intended human use.^[16] Our guide to research use only peptides explains why the disclaimer does not change the legal status.

For an influencer, this means a paid post demonstrating how to inject a “research” peptide can raise two problems at once: an undisclosed material connection under FTC rules, and evidence that the product is being sold as an unapproved drug.

A short checklist for advertisers

Clinics, pharmacies and creators who promote peptide services can test an ad against these questions:

• Does every health claim have human trial evidence behind it, not just animal or lab data?^[3]
• Is the approval status stated accurately, with no “FDA-approved,” “generic” or “same as” language for a compounded product?^[11]
• Is the compounding pharmacy or outsourcing facility identified accurately, without implying the advertiser made the drug?^[12]
• Are prices complete, including the drug, labs, visits and any membership commitment?^[9]
• Are testimonials real, typical, and paired with clear disclosure of any payment or free product?^[6][7]

State medical boards and clinician ads

Clinicians face a third layer. The FSMB’s May 2026 guidance says marketing of medical services must be “truthful, evidence-based, and not misleading,” including “wellness” offerings, and that clinicians must not misrepresent expected results and should be able to back claims with documented evidence.^[15] See state medical board peptide therapy rules.

How to read a peptide ad

• “FDA-approved” next to a compounded or research peptide is a red flag.
• “Same as” a brand-name drug, for a compounded product, is a claim FDA has called misleading.
• Look for human trial evidence, not only animal studies.
• Check the full price, including the drug, labs and any membership commitment.

This is general information, not legal advice.